Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2

An Emergency Use Authorization was issued in the United States and in Europe for a monoclonal antibody monotherapy to prevent severe COVID-19 in high-risk patients. This study aimed to assess the risk of emergence of mutations following treatment with a single monoclonal antibody. Bamlanivimab was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Peiffer-Smadja, Nathan, Bridier-Nahmias, Antoine, Ferré, Valentine Marie, Charpentier, Charlotte, Garé, Mathilde, Rioux, Christophe, Allemand, Aude, Lavallée, Philippa, Ghosn, Jade, Kramer, Laura, Descamps, Diane, Yazdanpanah, Yazdan, Visseaux, Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402761/
https://www.ncbi.nlm.nih.gov/pubmed/34452507
http://dx.doi.org/10.3390/v13081642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402761/
https://www.ncbi.nlm.nih.gov/pubmed/34452507
http://dx.doi.org/10.3390/v13081642

Ejemplares similares